Summary

Eligibility
for people ages 21-80 (full criteria)
Location
at UCLA
Dates
study started
estimated completion

Description

Summary

This study is a prospective, phase 2 extension study of participants previously enrolled in NTMT-01 and of participants enrolled in NTMT-02. This study is designed to evaluate long term safety and efficacy of the NT-501 implant in participants previously enrolled in the NTMT-01 and NTMT-02 protocols.

Keywords

Macular Telangiectasia Telangiectasis Ciliary neurotrophic factor (CNTF) Surgery

Eligibility

You can join if…

Open to people ages 21-80

  • Previously enrolled in the NTMT-01 or NTMT-02 protocol and received the NT-501 implant and/or underwent a Sham procedure
  • Participant must be offered sufficient opportunity to review and to understand the informed consent form, agree to the form's contents, and provide written informed consent.

You CAN'T join if...

  • There are no Exclusion Criteria

Locations

  • Stein Eye Institute / David Geffen School of Medicine
    Los Angeles California 90095 United States
  • University of Wisconsin-Madison, Department of Ophthalmology and Visual Sciences
    Madison Wisconsin 53705 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Neurotech Pharmaceuticals
ID
NCT03071965
Phase
Phase 2
Study Type
Interventional
Last Updated